DE69724796D1 - Biphasische orale verhuetungsmethode und kit die eine kombination von progestin und eines oestrogens enthalten - Google Patents

Biphasische orale verhuetungsmethode und kit die eine kombination von progestin und eines oestrogens enthalten

Info

Publication number
DE69724796D1
DE69724796D1 DE69724796T DE69724796T DE69724796D1 DE 69724796 D1 DE69724796 D1 DE 69724796D1 DE 69724796 T DE69724796 T DE 69724796T DE 69724796 T DE69724796 T DE 69724796T DE 69724796 D1 DE69724796 D1 DE 69724796D1
Authority
DE
Germany
Prior art keywords
estrogen
daily dosage
combination
phase
progestin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69724796T
Other languages
English (en)
Other versions
DE69724796T2 (de
Inventor
Jay Gast
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of DE69724796D1 publication Critical patent/DE69724796D1/de
Application granted granted Critical
Publication of DE69724796T2 publication Critical patent/DE69724796T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Communication Control (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines Containing Plant Substances (AREA)
DE69724796T 1996-07-26 1997-07-23 Biphasische orale verhuetungsmethode und kit die eine kombination von progestin und eines oestrogens enthalten Expired - Fee Related DE69724796T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69042296A 1996-07-26 1996-07-26
US690422 1996-07-26
PCT/US1997/012787 WO1998004265A1 (en) 1996-07-26 1997-07-23 Biphasic contraceptive method and kit comprising a combination of a progestin and estrogen

Publications (2)

Publication Number Publication Date
DE69724796D1 true DE69724796D1 (de) 2003-10-16
DE69724796T2 DE69724796T2 (de) 2004-07-01

Family

ID=24772384

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69724796T Expired - Fee Related DE69724796T2 (de) 1996-07-26 1997-07-23 Biphasische orale verhuetungsmethode und kit die eine kombination von progestin und eines oestrogens enthalten

Country Status (12)

Country Link
EP (1) EP0921804B1 (de)
JP (1) JP2000515889A (de)
KR (1) KR20000029536A (de)
CN (1) CN1186023C (de)
AT (1) ATE249222T1 (de)
AU (1) AU4043597A (de)
CA (1) CA2261748A1 (de)
DE (1) DE69724796T2 (de)
DK (1) DK0921804T3 (de)
ES (1) ES2205252T3 (de)
PT (1) PT921804E (de)
WO (1) WO1998004265A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4344462C2 (de) 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
FR2754179B1 (fr) 1996-10-08 1998-12-24 Theramex Nouvelle composition hormononale et son utilisation
FR2801218B1 (fr) * 1999-11-23 2001-12-28 Hoechst Marion Roussel Inc Compositions pharmaceutiques comprenant de la trimegestone, leurs procedes de preparation ainsi que le conditionnement primaire les renfermant
EP1535618A1 (de) * 2003-11-26 2005-06-01 Schering Aktiengesellschaft Pharmazeutische Zubereitung zur kontinuierlichen hormonellen Behandlung über einen Zeitraum von über 21-28 Tage beinhaltend zwei Estrogen und/oder Progestin Zusammensetzungen
DE102004019743B4 (de) * 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
DE102005034498A1 (de) * 2005-07-20 2007-01-25 Grünenthal GmbH Orale Kontrazeption mit Trimegeston
ES2322479T3 (es) * 2005-10-13 2009-06-22 Bayer Schering Pharma Aktiengesellschaft Utilizacion de valerato de estradiol en combinacion con dienogest para la terapia por via oral de la hemorragia uterina disfuncional, en union con una contracepcion oral.
EP1930010A1 (de) 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido
WO2008049172A1 (en) * 2006-10-27 2008-05-02 Vision Biosystems Limited A method and apparatus for dispensing substrates

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4308406C1 (de) * 1993-03-12 1994-06-16 Jenapharm Gmbh Kombinationspräparat zur Kontrazeption
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung

Also Published As

Publication number Publication date
WO1998004265A1 (en) 1998-02-05
AU4043597A (en) 1998-02-20
DE69724796T2 (de) 2004-07-01
EP0921804A1 (de) 1999-06-16
KR20000029536A (ko) 2000-05-25
CA2261748A1 (en) 1998-02-05
PT921804E (pt) 2004-01-30
CN1186023C (zh) 2005-01-26
EP0921804B1 (de) 2003-09-10
ES2205252T3 (es) 2004-05-01
ATE249222T1 (de) 2003-09-15
CN1226167A (zh) 1999-08-18
DK0921804T3 (da) 2003-11-24
JP2000515889A (ja) 2000-11-28

Similar Documents

Publication Publication Date Title
DE69729956D1 (de) Orale einstufige empfängnisverhütungsmethode und kombinationspräparat das gestagen und estrogen enthält
DK0491438T3 (da) Svangerskabsforebyggende behandling
DK365887D0 (da) Kombinationsdoseringsform til hormonbehandling af kvinder i prae-menopausen
DK0491415T3 (da) Orale svangerskabsforebyggende midler med lavt østrogen
CY1105276T1 (el) Τριφασικο στοματικο αντισυλληπτικο
WO1998004246A3 (en) Triphasic contraceptive method and kit comprising a combination of a progestin and estrogen
DK0917466T3 (da) Oralt antikonceptionsmiddel
DE69724796D1 (de) Biphasische orale verhuetungsmethode und kit die eine kombination von progestin und eines oestrogens enthalten
KR890009407A (ko) 폐경기증세 및 골다공증의 치료를 위한 약학적 투여단위

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee